ClinicalTrials.gg
RecruitingNCT05411666OTIMACATUpdated Aug 15, 2025

Maintenance Optimization of the Fully Implanted Venous Catheter

An interventional study of Saline solution maintenance of the CVC and No maintenance of the CVC in Cancer, sponsored by Clinical Academic Center (2CA-Braga). Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Clinical Academic Center (2CA-Braga) · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 10 months after the study started (first participant enrolled Jun 2020, registered May 2022).
  • Started Jun 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Central venous catheter (CVC) are intravascular devices used in clinical practice, namely to administer fluid therapy, parenteral nutrition, drugs, blood products, hemodynamic monitoring, also being a gateway to the collection of blood samples or laboratory monitoring.

The fully implanted central venous catheter (CVCTI) is a type of central venous access surgically placed, which is characterized by containing a subcutaneous reservoir that is accessed by puncturing the camera with a blunt needle, widely used in cancer patients. The fully implanted central venous catheter is recommended when there is a need for intermittent vascular access and of long duration.

The maintenance of the CVCTI, as it's the necessity, frequency, and method is subject of some controversy, with discrepancies between the various cancer centers and guidance documents, once they occur several different intervals and maintenance methods.

The objective of this study is to assess the necessity of frequent maintenance of fully implanted central venous catheter, still assuring its viability and holding the same or lower number incidence of complications.

Participants in this study are cancer patients with a CVC fully implanted for chemotherapy, in follow-up phase. Participants will be randomized in one of two arms: Maintenance with saline solution and no maintenance.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Central venous catheter
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 176 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Clinical Academic Center (2CA-Braga) is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age.
  • Cancer patients, undergoing placement of CVCTI for chemotherapy, in follow-up, who finished chemotherapy up to a maximum period of 10 weeks.
  • (ECOG) status of 0 or 1
  • Evidence of signed and dated indicating that the patient has been informed of all relevant aspects of the study and agrees to participate.

Exclusion criteria

Exclusion Criteria:

  • Presence of or any other condition that may be an indication for intravenous treatments or additional chemotherapy regimens
  • History of CVCTI-related adverse events during the treatment phase
  • Patients on anticoagulant medication
  • History of thrombophilia
  • Pregnancy/Breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (estimated)

Study arms

  • Other
    Arm 1

    Saline solution maintenance of the Central venous catheter (CVC)

    Procedure: Saline solution maintenance of the CVC

  • Experimental
    Arm 2

    No maintenance of the Central venous catheter (CVC)

    Procedure: No maintenance of the CVC

Interventions

  • ProcedureSaline solution maintenance of the CVC

    Saline solution maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun, according to local standard procedures.

    Also known as: Saline solution maintenance

  • ProcedureNo maintenance of the CVC

    No maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun. Just visual inspection to local site of CVC insertion.

    Also known as: No maintenance

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    The occurrence of any adverse event related to the use of the CVCTI, thus allowing to assess the difference between the 2 groups with as much data as possible.

    Time frame: Time since screening until follow-up visit (on average 20 months)

Secondary outcomes

  1. Occurence of AE related with infectious complications

    The occurrence of adverse events related to infectious complications in the 2 groups.

    Time frame: Time since screening until follow-up visit (on average 20 months)

  2. Occurence of AE related with thrombotic complications

    The occurrence of adverse events related to thrombotic complications of both CVCTI and venous thrombosis in both groups.

    Time frame: Time since screening until follow-up visit (on average 20 months)

07

Study locations

1 of 1 sites recruiting
  • Serviço de Hospital de Dia, Hospital de Braga
    Braga, 4710-243, Portugal
    Recruiting
    • Rosana Magalhaes · Contact00351 253 027249
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jun 2026, 72 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 72 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 9, 2022
StartActual
Jun 30, 2020
Primary completionEst.
Jun 2026
CompletionEst.
Jul 2026
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05411666
Lead sponsor
Clinical Academic Center (2CA-Braga)
Responsible party
Sponsor
First posted
Jun 9, 2022
Start date
Jun 30, 2020
Primary completion
Jun 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Aug 15, 2025

Study contacts

Rosana Magalhaes
Contact
cro@ccabraga.org
+351 253 027 249
Ema Alves
principal investigator · Serviço de Hospital de Dia, Hospital de Braga, EPE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion